00:00One dose of a psychedelic compound was linked to improvements in depression symptoms within
00:05just two days. The finding comes from a small clinical trial in Sweden involving 35 adults
00:11with moderate to severe recurrent depression. Researchers compared a single 25-milligram
00:16dose of psilocybin with niacin, a vitamin used as an active placebo. Both groups also received
00:23psychological support before and after treatment. By day eight, the psilocybin group showed a
00:28significantly greater reduction in clinician-rated depression scores. At six weeks, around 53% of the
00:35psilocybin group were in remission, compared with just 6% in the placebo group. But the findings come
00:42with important limitations. The study was small, and two participants experienced severe persistent
00:48anxiety requiring medical attention. By one year, the difference between the groups was no longer
00:53statistically significant. Researchers are now investigating how psilocybin may affect brain
00:59connections. The results are promising, but larger studies are needed before its long-term benefits
01:05and safety can be established. Disclosure, this video contains stock footage and content created
01:09or enhanced using AI-assisted tools.
Comments